New technologies and screening strategies for hepatotoxicity: use of in vitro models.
about
Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategyEvaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicityKey Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansIdentification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model systemIn vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.Assessment of compound hepatotoxicity using human plateable cryopreserved hepatocytes in a 1536-well-plate format.Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions.Opportunities for use of human iPS cells in predictive toxicologyMaximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.In silico models for drug-induced liver injury--current status.Drug safety testing paradigm, current progress and future challenges: an overview.Competency of different cell models to predict human hepatotoxic drugs.High-content screening technology for studying drug-induced hepatotoxicity in cell models.Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitorsCurrent limitations and future opportunities for prediction of DILI from in vitro.Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.Salvianolic acid A attenuates TNF-α- and D-GalN-induced ER stress-mediated and mitochondrial-dependent apoptosis by modulating Bax/Bcl-2 ratio and calcium release in hepatocyte LO2 cells.3D Cultivation Techniques for Primary Human Hepatocytes.A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.Equine hepatocytes: isolation, cryopreservation, and applications to in vitro drug metabolism studies.Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.Toxicological assessment of industrial solvents using human cell bioassays: assessment of short-term cytotoxicity and long-term genotoxicity potential.Long-term culture of primary hepatocytes: new matrices and microfluidic devices.Decellularized skeletal muscle as an in vitro model for studying drug-extracellular matrix interactions.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates.Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis: Regulation of p53 Signaling Pathway in HepG2 Cells In Vitro.Toxicity testing of four silver nanoparticle-coated dental castings in 3-D LO2 cell cultures.On chip two-photon metabolic imaging for drug toxicity testing.Multiparametric evaluation of the cytoprotective effect of the Mangifera indica L. stem bark extract and mangiferin in HepG2 cells.Toxic Effects of Titanium Dioxide Nanoparticles and Titanium Dioxide Bulk Salt in the Liver and Blood of Male Sprague-Dawley Rats Assessed by Different Assays.
P2860
Q21223673-6E4D2070-F1A9-493B-97F3-660352202B10Q27027301-CA1CE83E-67E6-453F-98E2-CA5B922319D2Q28075991-810C7D18-4312-41C1-9375-BC61A91C959FQ28477163-81B9FB31-37FD-4FAC-8004-25AE4037261CQ30452333-607DAB33-CCEA-4F40-B24A-BF10C1B2A8ABQ34044936-A0C11939-90EA-4B75-BB29-B1168811B6DFQ34067184-8A85251D-38B1-4A43-A95E-D63FCC66FF60Q35646205-2D36A1AC-09D6-46B8-BE82-E057E337371CQ35828228-4310F419-EFFE-4C34-8930-B3D0F840F17FQ36662857-0A277B0F-D289-4D45-8C45-05ED787E2EDBQ36672246-187497D0-EBE5-47D6-A1B5-D95E9ABEC8D2Q36960535-CD254821-AD31-4997-B0AF-5E6D01C6E8D3Q37121662-51EF4701-12E8-42FD-93B6-740578DC9B5CQ37921314-6133E424-DF8B-4867-B199-143BF4CA43EBQ37976120-465BD6AA-A5AC-4152-8945-FA4485013DAFQ38207946-9208F861-A412-4FA4-9F3D-A30FC599370FQ38258251-2A0C5CB6-3C7D-4EF9-9B56-C8EFE11E9766Q38383132-F01C7924-57CA-425F-9B53-FBE89901927CQ38675826-F7FA0129-7AE4-4C02-88B7-6E5CAC8B3564Q38732067-CD567693-A398-45EE-8A9C-2B35E6C406D2Q38739197-A0CB5093-9526-4228-9045-60A6A0BACF0DQ38763000-715E681E-BEAD-480A-8AE6-A244BA87CAE0Q38843888-1EAD3111-2776-45DF-9A89-C22C71F45AD7Q38878861-7E8045AE-B226-4CD2-8C1D-20F34F846E3EQ38947618-7521CD9D-3C9D-4F8E-B3D1-9FC372F76A19Q39089080-B28BF0C5-9E68-4D73-8B21-B253B541E225Q39314599-837D18BD-468D-4F7E-965F-9DFB7E7D0411Q39348237-5BE8AA4D-8766-4655-8FB5-3F584C0BF752Q39735921-8154536E-C244-4123-893F-3A6270C3A799Q40223429-482E368C-0EE4-41C6-88A5-7DFE949BBAB8Q40706098-2FF148C2-C001-4AD8-8CD8-5512B550CA34Q40782298-C1E89C7E-45EA-4B38-91ED-622C8A6B6340Q41051252-AB8B5ACA-BD6A-413F-B9F0-ABB772E3BEACQ46981409-5512F0EE-3C38-4FD3-8F2F-973F9C643347Q49219661-01EDD45F-04DF-41D2-9F76-60E88E92B866Q49256920-B4584D10-5864-4AF8-B187-D1114FF19FD5Q50060535-64054A25-ADD0-480E-B241-9A10DA456814Q50632568-7EE09A06-1746-439A-AEBD-75DD5C36923EQ50935127-A07E33E3-D0E2-46B2-B45E-5DE55335935EQ53764602-13AD705C-E9E7-4E9A-9469-CE9076C421FE
P2860
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@ast
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@en
type
label
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@ast
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@en
prefLabel
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@ast
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@en
P2093
P2860
P1476
New technologies and screening strategies for hepatotoxicity: use of in vitro models.
@en
P2093
Barbara A Andrews
Donna M Dambach
Frederic Moulin
P2860
P356
10.1080/01926230590522284
P407
P577
2005-01-01T00:00:00Z